Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 201

Sort by

Sort Order Select

Journal Articles

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Evangelia Antoniou, Lina Marie Hoffmeister, Nils Von Neuhoff, Dirk Reinhardt, Markus Schneider, Stephanie Sendker

Blood (2024) 144 (Supplement 1): 228.

https://doi.org/10.1182/blood-2024-208718

Published: 2024

Journal Articles

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Blood (2024) 144 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2024-200574

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Eva Rettinger, Martin Hutter, Birte Karschen, Evangelia Antoniou, Peter Bader, Rita Beier, Birgit Burkhardt, Ursula Creutzig, Gabriele Escherich, Jan-Henning Klusmann, Peter Lang, Naghmeh Niktoreh, Martin G. Sauer, Stephanie Sendker, Dirk Reinhardt, Katharina Waack

Blood (2024) 144 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2024-208311

Published: 2024

Journal Articles

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

Amin T. Turki, Alberto Hernández Sánchez, Wellington Silva, Magdalena Karasek, Luca Guarnera, Koray Yalçin, Amir Enshaei, Marta Sobas, Dirk Reinhardt, Maria M Rivas, Deepak Kumar Mishra, Eduardo Rego, Ahmet Koc, Paola Núñez Medina, Maria Teresa Voso, Anthony Moorman, Felix Nensa, Merlin Engelke

Blood (2024) 144 (Supplement 1): 790.

https://doi.org/10.1182/blood-2024-207058

Published: 2024

Journal Articles

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Stephanie Sendker, Jens Gehlen, Tabea Ziedrich, Evangelia Antoniou, Markus Schneider, Nils Von Neuhoff, Dirk Reinhardt, Lina Marie Hoffmeister

Blood (2024) 144 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2024-208614

Published: 2024

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Martina Pigazzi, Claudia Tregnago, Rhonda E Ries, Maddalena Benetton, Todd A. Alonzo, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils Von Neuhoff, Henrik Hasle, Dirk Reinhardt, Franco Locatelli, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 840.

https://doi.org/10.1182/blood-2023-181872

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Evangelia Antoniou, Annika Puschnig, Lina Marie Hoffmeister, Amani Awada, Nils Von Neuhoff, Markus Schneider, Dirk Reinhardt, Naghmeh Niktoreh

Blood (2023) 142 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2023-187465

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Blood (2023) 141 (10): 1105–1118.

https://doi.org/10.1182/blood.2022017619

Published: 2023

Includes: Supplemental data

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Katharina Waack, Katharina Andernacht, Christiane Walter, Markus Schneider, Nils Von Neuhoff, Sophia Hahn, Amani Awada, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6326–6327.

https://doi.org/10.1182/blood-2022-169495

Published: 2022

Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan

Blood (2022) 140 (Supplement 1): 3369–3370.

https://doi.org/10.1182/blood-2022-168818

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Downregulation of the Mutated WT1 Alleles in Malignant Hematopoietic Cells Via Nonsense-Mediated mRNA Decay Contradicts Their Prognostic Impact

Lisa Weber, Christiane Walter, Markus Schneider, Hans Günther Drexler, Dirk Reinhardt, Helmut Hanenberg, Naghmeh Niktoreh

Blood (2022) 140 (Supplement 1): 11498–11499.

https://doi.org/10.1182/blood-2022-168591

Published: 2022

Journal Articles

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Stephanie Sendker, Markus Schneider, Amani Awada, Eser Orhan, Michael Sendker, Lina Hoffmeister, Evangelia Antoniou, Dirk Reinhardt, Nils Von Neuhoff

Blood (2022) 140 (Supplement 1): 9110–9112.

https://doi.org/10.1182/blood-2022-167465

Published: 2022

Journal Articles

Guiding Pups with Severe Hemophilia a and Their Parents from Diagnosis to a Full Prophylactic Schedule Mitigating the Risk of Bleed and the Risk for Inhibitor Formation - a Single Centre Approach

Susan Halimeh, Hannelore Rott, Manuela Siebert, Günther Kappert, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 8472–8473.

https://doi.org/10.1182/blood-2022-168988

Published: 2022

NARROW

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Europeanpediatric Acute Leukemia (EuPAL) Registry

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Downregulation of the Mutated WT1 Alleles in Malignant Hematopoietic Cells Via Nonsense-Mediated mRNA Decay Contradicts Their Prognostic Impact

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Guiding Pups with Severe Hemophilia a and Their Parents from Diagnosis to a Full Prophylactic Schedule Mitigating the Risk of Bleed and the Risk for Inhibitor Formation - a Single Centre Approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only